CAR T-Cell Therapy Offers Hope in DLBCL

Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann, M.D., professor at the University Hospital of Cologne in Germany.

The phase 2 trial is investigating the CAR-T cell therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory DLBCL. Borchmann explained that at the median follow-up of 14 months, the researchers are still seeing a high amount of patients who are responding to treatment. While longer observation is needed, he said that the findings from this study are generating hope that more patients with DLBCL can obtain and remain in remission.